Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
September 03, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences...
Processa Pharmaceuticals Provides Product Pipeline and Financial Update
August 28, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri...
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
July 17, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next...
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
June 03, 2024 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
March 28, 2024 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
March 25, 2024 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
February 01, 2024 16:22 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
January 02, 2024 17:06 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
December 13, 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA provides guidance on Phase 2 design and Processa to continue with pre-study activities for Phase 2 trial HANOVER, MD, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq:...
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
November 13, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...